Printer Friendly

R.P. SCHERER ANNOUNCES NEW EVIDENCE FOR COLONIC DRUG DELIVERY

 TROY, Mich., Nov. 18 ~PRNewswire~ -- R.P. Scherer Corporation (NYSE: SHR) announced today new evidence supporting the use of its PULSINCAP(TM) dosage form for delivery of drugs to the colonic area of the gastro-intestinal tract. The announcement was made in a scientific paper presented to the annual national meeting of the American Association of Pharmaceutical Scientists in San Antonio, Texas. The results of studies using the PULSINCAP(TM) device in human volunteers were presented by Dr. Howard Stevens, Operations Director for the Scherer DDS Division of R.P. Scherer Corporation.
 The PULSINCAP(TM) dosage form is an oral drug delivery system which releases drug at a pre-determined time or place within the gastro- intestinal tract. The device essentially consists of an impermeable capsule body containing the drug, fitted with a hydrogel plug. In aqueous media the plug hydrates, swells and, after a time period defined by the plug dimensions, is ejected from the device, thereby releasing the capsule contents. For delivery to the colon, an enteric or pH-sensitive coat is applied to the PULSINCAP(TM) device.
 In one study on three volunteers using the technique of gammascinitigraphy, it was demonstrated that a PULSINCAP(TM) device could remain intact in the stomach for up to seven hours, with subsequent rapid cap dissolution post-gastric emptying and plug ejection after a predicted time period. In a further study using radiolabelled PULSINCAP(TM) devices in six volunteers, it was shown that a capsule could remain intact throughout the stomach and small intestine and could release its contents on arrival in the ascending colon.
 Dr. Stevens comments "Despite the small numbers involved, these results give us great confidence that we shall be able to use PULSINCAP(TM) formulations to deliver drugs consistently and reliably to the colon. The PULSINCAP(TM) drug delivery system may prove to be of great value for treatment of inflammatory bowel disorders and for investigating the feasibility of colonic absorption of peptides."
 R.P. Scherer Corporation, an international developer and manufacturer of drug delivery systems, is the world's largest producer of soft gelatin capsules ("softgels"). The Company is currently developing and commercializing advanced drug delivery systems, including SCHERERSOL(R), ZYDIS(R) and PULSINCAP(TM) technologies. The Company's proprietary drug delivery systems improve the efficacy of drugs by regulating the dosage, rate of absorption and place of release. The Company operates a global network of 15 facilities in 11 countries.
 -0- 11~18~92
 ~CONTACT: Nicole Williams, Executive VP & CFO, R.P. Scherer Corporation, 313-649-0900~
 (SHR)


CO: R.P. Scherer Corporation ST: Michigan IN: MTC SU:

JG -- DE009 -- 2239 11~18~92 10:15 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 18, 1992
Words:434
Previous Article:PRECISE TECHNOLOGY & ELECTRONICS DIVISION OF AIR GAGE COMPANY WINS PRESTIGIOUS MICHIGAN'S LEADING EDGE TECHNOLOGIES AWARD
Next Article:METALCLAD HOLDS ANNUAL MEETING OF SHAREHOLDERS
Topics:


Related Articles
R.P. SCHERER ANNOUNCES EXPANSION OF ITS NORTH AMERICAN SOFTGEL CAPACITY
R.P. SCHERER ANNOUNCES AGREEMENT TO SELL PACO TERMINATED
SCHERER ANNOUNCES ZYDIS PRODUCT LAUNCH IN ITALY
SCHERER AND PACO ANNOUNCE SUCCESSFUL COMPLETION OF INITIAL OFFERING OF PACO'S COMMON STOCK
SCHERER AND CHESEBROUGH-POND'S JOINTLY DEVELOP A NEW SKIN MOISTURIZER CAPSULE
SCHERER ANNOUNCES LAUNCH OF ANOTHER PRODUCT UTILIZING ITS ZYDIS(R) TECHNOLOGY
R.P. SCHERER ANNOUNCES ACQUISITION IN SPAIN
SCHERER ANNOUNCES CREATION OF NEW DEVELOPMENT GROUP
R.P. SCHERER ANNOUNCES PULSINCAP(R) RESEARCH AGREEMENT
SCHERER PROVIDES UPDATE ON ADVANCED THERAPEUTIC PRODUCTS GROUP

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters